Michael Conte (San Francisco, USA), one of the co-editors of the recently published Global Vascular Global Vascular chronic limb threatening ischaemia (CLTI) Guideline, tells BLearning Peripheral about the simplified tools, including mobile apps and pocket references that are in the pipeline to help disseminate the document and its staging systems. One of the guideline’s specific recommendations is for randomised trials to continue enrolment to assess the potential benefits of using paclitaxel devices in CLTI patients. Ahead of the US FDA panel being convened in June, Conte maintains that while the risk-benefit ratio in claudicants may be “difficult to take on” there remains a great unmet need to improve the outcomes of endovascular therapy in CLTI patients. There is currently a glaring paucity of evidence demonstrating the benefit of using paclitaxel devices in this particular group, he says.
Subscribe to receive BLearning videos here: www.blearning.net/registration